GRACEcast (Blood-Cancers-Video)
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit for more info.

Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.

Direct download: 01_Jennifer_Brown_04_FCR_v_BR-_Is_one_better-.mp4
Category:Blood-Cancers-Video -- posted at: 7:37pm PDT

CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed.  Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.

Not Your Father's CLL

Faculty member Dr. John Pagel, and an in-person audience of patients and caregivers joined GRACE for 'Not Your Father's CLL', webcast LIVE from Seattle, WA on April 22, 2016.

Dr. Pagel, Chief of the Hematologic Malignancies program for the expanded treatment and research of blood based cancers such as leukemia, multiple myeloma and lymphoma at Swedish Cancer Institute, spoke about current treatment options and the future of care, and took questions from both the in-person and online audiences.  We invite you to watch the video.

Direct download: GRACEcast_-_Not_Your_Fathers_CLL_with_Dr._John_Pagel.mp4
Category:Blood-Cancers-Video -- posted at: 4:22pm PDT